CC chemokine receptor 5Δ32 polymorphism—a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation
✍ Scribed by Christian Moench; Anja Uhrig; Ansgar W. Lohse; Gerd Otto
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 94 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20095
No coin nor oath required. For personal study only.
✦ Synopsis
Ischemic-type biliary lesions are a major complication following orthotopic liver transplantation. They occur in up to 26% of liver transplant recipients. Among other factors, unknown immunologic factors have always been assumed to be partly responsible for these lesions. CCchemokines and their receptors play a key role in postoperative immunomodulation after liver transplantation. The non-function CC-chemokine receptor 5⌬32 polymorphism (CCR5⌬32) has been shown to lead to a lower rate of acute rejection after kidney transplantation; in liver transplantation the role of CCR5⌬32 is unclear. We investigated the influence of the CCR5⌬32 after liver transplantation with special regard to ischemic-type biliary lesions. The CC-chemokine receptor-5 (CCR5) of 146 recipients was analyzed by polymerase chain reaction to detect CCR5⌬32 in blood samples of patients after liver transplantation. One hundred twenty patients with wildtype CCR5 and 26 patients with CCR5⌬32 (1 homozygote, 25 heterozygote) were identified. Ischemic-type biliary lesions occurred in 14 of 120 patients with wild-type CCR5 and in 8 of 26 patients with CCR5⌬32 polymorphism (P ؍ ؍ 0.01). 5 year patient survival with CCR5⌬32 and CCR5 was 70% and 85%, respectively (P ؍ .0067). Our results show that the CCR5⌬32 is a significant risk factor for the development of ischemictype biliary lesions after liver transplantation and leads to a reduction in 5-year survival. In conclusion, the CCR5 status should be screened prospectively before liver transplantation. (Liver